621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides crucial real-world evidence supporting the sustained renal benefits of oral semaglutide when patients transition from injectable GLP-1RAs. The convenience of an oral formulation could significantly…
This review provides a critical safety alert for clinicians prescribing semaglutide, emphasizing the need for increased vigilance regarding ocular symptoms. The findings suggest that patients on semaglutide should be …
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
A successful semaglutide nasal spray could offer a more convenient and potentially less invasive administration route for patients managing overweight or obesity. This novel delivery method could significantly improve…
Reducing NETosis could represent a novel therapeutic strategy for managing inflammation and progression in diabetic kidney disease and immune-mediated kidney diseases. Identifying specific drug classes like SGLT2 inhi…
This research is crucial for understanding the precise behavioral mechanisms through which GLP-1 receptor agonists promote weight loss, moving beyond self-reported data to direct observation. The identification of spe…
Oral semaglutide could offer a safer, more effective, and convenient alternative to insulin for managing post-transplant hyperglycemia, potentially mitigating risks like hypoglycemia and weight gain in a highly vulner…
This study is crucial for understanding how Semaglutide performs in a diverse patient population under typical healthcare conditions, rather than idealized trial environments. Real-world evidence complements tradition…
This perspective is crucial for understanding the potential challenges and benefits of using oral semaglutide in patients who have undergone MBS. It suggests that while the drug's mechanism of action is highly relevan…
This study provides a robust, scientifically-driven methodology for developing complex oral peptide formulations like semaglutide, potentially leading to more effective and patient-friendly treatment options. The enha…
This study provides compelling evidence for semaglutide's potential as a preventative pharmacological agent against life-threatening aortic events like rupture and dissection. Given the current lack of drug treatments…
This real-world study provides crucial insights into the practical application and effectiveness of semaglutide in a challenging patient population with Cardiovascular-Kidney-Metabolic Syndrome (CKM). The findings und…
This study provides compelling direct evidence that GLP-1 RAs acutely enhance the contractility of human heart muscle, independent of their systemic metabolic effects. This direct positive inotropic effect could be a …
The widespread prevalence of low-quality and misleading information about semaglutide on social media platforms poses a significant public health risk. This can lead to inappropriate self-medication, incorrect dosing,…
This review underscores the transformative potential of novel antiobesity medications in improving cardiovascular health outcomes for obese patients. The demonstrated 20% reduction in MACE by semaglutide sets a new be…
This comprehensive review underscores the critical role of the gut microbiome as a mediator of GLP-1 therapy effects on liver health, particularly in patients with Type 2 Diabetes Mellitus. Understanding these mechani…
The study demonstrated significant reductions in alcohol consumption and body weight in the semaglutide group compared to placebo. > Patients treated with semaglutide experienced a 43% reduction in weekly alcohol inta…
This study provides compelling evidence that Semaglutide offers significant cardiovascular protection beyond its established benefits for weight loss and diabetes management. This establishes Semaglutide as a crucial …
The review identified that GLP-1 RAs exert effects far beyond simple caloric restriction, significantly impacting neural circuits involved in reward processing and impulse control. They found that these agents can mod…
The potential introduction of a high-dose semaglutide (Wegovy HD) could offer a new, more potent option for individuals struggling with obesity who may not achieve sufficient weight loss with current treatments. If th…
This research represents a significant step towards personalized medicine in the treatment of obesity and type 2 diabetes. By understanding the genetic underpinnings of GLP-1 RA response, clinicians could potentially …
Understanding the role of hematopoietic stem cells and inflammation in T2D's cardiovascular risk could revolutionize treatment strategies. If semaglutide proves effective in reversing these inflammatory and cellular c…
Understanding the link between neuropathy and semaglutide-induced gastric retention is crucial for optimizing patient care and safety. This research could lead to improved risk stratification for diabetic patients con…
The successful completion of a bioequivalence study is a critical step in the drug development process, particularly for generic versions or new formulations of existing medications. Demonstrating bioequivalence means…
This study provides compelling real-world evidence that oral semaglutide not only improves glycemic control and promotes weight loss but also significantly reduces systemic inflammation in patients at high cardiovascu…
This meta-analysis provides compelling evidence of a potential association between GLP-1RA use and an increased risk of NAION, highlighting a crucial ocular safety consideration for millions of patients. Given the wid…
This study provides crucial real-world evidence, reinforcing that semaglutide offers significant benefits for patients with type 2 diabetes beyond just managing blood sugar and weight. The observed improvements in kid…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
This study is crucial because it addresses a highly underserved patient group: individuals with severe obesity and multimorbidity who cannot undergo bariatric surgery. The findings could establish a new, effective tre…
Understanding the specific metabolic changes induced by CagriSema versus diet-induced weight loss is crucial for optimizing obesity treatment strategies. If CagriSema demonstrates superior or distinct metabolic benefi…
This study provides compelling evidence that semaglutide could be a groundbreaking treatment option for individuals struggling with Alcohol Use Disorder, particularly those with comorbid obesity. Given the high global…
The preservation of bone health during weight loss is a critical consideration, especially for postmenopausal women who are already susceptible to bone density loss and fracture risk. This study is significant because…
This study provides compelling evidence that GLP-1 medicines may offer substantial benefits beyond their primary role in weight loss and metabolic health. The observed improvements in mental health, eating disorder sy…
This study provides compelling preliminary evidence that semaglutide, a well-known GLP-1 receptor agonist, could be a highly effective and novel treatment for intractable diarrhea, offering a new therapeutic option fo…
The findings from this review are highly significant, suggesting that modern antidiabetic drugs offer more than just blood sugar control. They may directly improve outcomes for patients with Peripheral Arterial Occlus…
This comprehensive review is vital for enhancing awareness among clinicians and patients regarding the potential ocular risks associated with GLP-1 RA treatment. It provides a crucial framework for identifying vulnera…
This research introduces a groundbreaking approach to treating obesity and diabetes by simultaneously targeting multiple metabolic pathways. By combining GLP-1R, GIPR, and PPARα/γ/δ agonism, this strategy could offer …
These findings are highly significant as they indicate that Lotiglipron has a low propensity for drug-drug interactions with a broad range of commonly used medications. This favorable DDI profile simplifies its potent…
This comprehensive review is critically important as it establishes a robust scientific rationale for further investigating GLP-1 RAs as a novel and potentially transformative therapeutic strategy for psoriasis, espec…
These findings are highly significant, suggesting a novel therapeutic avenue for addressing anhedonia and motivational deficits in Major Depressive Disorder, symptoms that are notoriously difficult to treat with exist…
This study reveals a notable disparity in the utilization of GLP1RAs among individuals with multiple sclerosis who possess cardiometabolic comorbidities that would warrant such treatment. The findings underscore the i…
The development of CagriSema is significant because it combines two potent mechanisms: Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist), potentially offering synergistic effects for greater w…
If successful, this study could usher in a new era of precision medicine for obesity, moving beyond a 'one-size-fits-all' approach. The ability to use a simple saliva test to predict semaglutide efficacy could signifi…